4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 81 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $51,014,367 | -29.6% | 4,007,413 | 0.0% | 1.38% | -31.8% |
| Q2 2023 | $72,413,953 | +5.1% | 4,007,413 | 0.0% | 2.02% | -19.9% |
| Q1 2023 | $68,887,429 | -22.6% | 4,007,413 | 0.0% | 2.52% | -33.0% |
| Q4 2022 | $89,004,643 | +176.2% | 4,007,413 | 0.0% | 3.76% | +182.2% |
| Q3 2022 | $32,220,000 | +15.2% | 4,007,413 | 0.0% | 1.33% | -1.5% |
| Q2 2022 | $27,972,000 | -30.6% | 4,007,413 | +50.4% | 1.35% | -16.2% |
| Q1 2022 | $40,288,000 | -8.5% | 2,664,521 | +32.8% | 1.61% | +0.9% |
| Q4 2021 | $44,009,000 | -18.6% | 2,005,862 | 0.0% | 1.60% | -24.3% |
| Q3 2021 | $54,098,000 | +12.0% | 2,005,862 | 0.0% | 2.11% | +16.6% |
| Q2 2021 | $48,301,000 | +8.0% | 2,005,862 | +94.5% | 1.81% | +7.9% |
| Q1 2021 | $44,728,000 | -2.4% | 1,031,070 | -6.8% | 1.68% | -7.0% |
| Q4 2020 | $45,847,000 | – | 1,106,070 | – | 1.80% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VR Adviser, LLC | 3,000,000 | $38,190,000 | 4.02% |
| Casdin Capital, LLC | 1,033,811 | $13,160,414 | 1.46% |
| BVF INC/IL | 4,007,413 | $51,014,367 | 1.38% |
| Deep Track Capital, LP | 2,778,107 | $35,365,302 | 1.36% |
| Opaleye Management Inc. | 308,500 | $3,927,205 | 1.28% |
| Eagle Health Investments LP | 437,911 | $5,574,607 | 1.23% |
| Novo Holdings A/S | 1,200,000 | $15,276,000 | 1.13% |
| RA Capital Management | 4,163,211 | $52,997,676 | 1.04% |
| VIKING GLOBAL INVESTORS LP | 4,787,914 | $60,950,145 | 0.25% |
| HighVista Strategies LLC | 33,419 | $425,424 | 0.20% |